GO Capital Fund

LeddarTech Inc. specializes in advanced detection and ranging systems using time-of-flight measurement technology with infrared LEDs. The company offers a range of smart sensor modules, including single-element and multi-element systems tailored for various applications, such as industrial, traffic management, and smart home solutions. LeddarTech's technology is particularly focused on enhancing advanced driver assistance systems (ADAS) and autonomous driving by providing perception solutions that integrate data from various sensor types, including cameras and radar. Their flagship platform, LeddarVision™, facilitates the creation of comprehensive 3D environmental models, addressing critical challenges in environmental sensing and perception. With over 140 patents granted or pending, LeddarTech is committed to innovation in the automotive sector, serving original equipment manufacturers (OEMs) and automotive suppliers to accelerate development cycles and improve time-to-market. Founded in 2007 and based in Quebec City, Canada, the company also maintains a research and development office in Toronto.

Alethia BioTherapeutics, Inc. is a biotechnology company based in Montreal, Canada, specializing in the discovery and development of monoclonal antibody-based therapeutics. The company focuses on critical areas such as cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and cancer-induced bone loss. Its product portfolio includes Isogranulatimide, a G2 checkpoint inhibitor that enhances the efficacy of various DNA-damaging chemotherapeutic agents, and sCLU, a glycoprotein linked to several malignancies, including prostate and breast cancers. Additionally, Alethia BioTherapeutics offers AB-0447, which targets a specific antigen prevalent in over eighty-five percent of ovarian cancer cases, and AB-0440, a protein that plays a role in osteoclast differentiation. Established in 2002, the company employs patented STAR discovery technology to develop therapeutics aimed at invasive carcinomas and associated complications.

Alethia BioTherapeutics, Inc. is a biotechnology company based in Montreal, Canada, specializing in the discovery and development of monoclonal antibody-based therapeutics. The company focuses on critical areas such as cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and cancer-induced bone loss. Its product portfolio includes Isogranulatimide, a G2 checkpoint inhibitor that enhances the efficacy of various DNA-damaging chemotherapeutic agents, and sCLU, a glycoprotein linked to several malignancies, including prostate and breast cancers. Additionally, Alethia BioTherapeutics offers AB-0447, which targets a specific antigen prevalent in over eighty-five percent of ovarian cancer cases, and AB-0440, a protein that plays a role in osteoclast differentiation. Established in 2002, the company employs patented STAR discovery technology to develop therapeutics aimed at invasive carcinomas and associated complications.

Leap Medical, Inc. engages in designing, developing, manufacturing, and marketing products that provide the earliest possible indicators of a patient's medical condition. The company is based in Montreal, Canada.

Alethia BioTherapeutics, Inc. is a biotechnology company based in Montreal, Canada, specializing in the discovery and development of monoclonal antibody-based therapeutics. The company focuses on critical areas such as cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and cancer-induced bone loss. Its product portfolio includes Isogranulatimide, a G2 checkpoint inhibitor that enhances the efficacy of various DNA-damaging chemotherapeutic agents, and sCLU, a glycoprotein linked to several malignancies, including prostate and breast cancers. Additionally, Alethia BioTherapeutics offers AB-0447, which targets a specific antigen prevalent in over eighty-five percent of ovarian cancer cases, and AB-0440, a protein that plays a role in osteoclast differentiation. Established in 2002, the company employs patented STAR discovery technology to develop therapeutics aimed at invasive carcinomas and associated complications.